Prostate cancer antigen 3 to select men for prostate biopsy: stop, go, or proceed with caution?
Publication
, Journal Article
Abern, MR; Freedland, SJ
Published in: Eur Urol
February 2013
Duke Scholars
Published In
Eur Urol
DOI
EISSN
1873-7560
Publication Date
February 2013
Volume
63
Issue
2
Start / End Page
210 / 211
Location
Switzerland
Related Subject Headings
- Urology & Nephrology
- Prostatic Neoplasms
- Prostate
- Nomograms
- Male
- Humans
- Antigens, Neoplasm
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Abern, M. R., & Freedland, S. J. (2013). Prostate cancer antigen 3 to select men for prostate biopsy: stop, go, or proceed with caution? Eur Urol, 63(2), 210–211. https://doi.org/10.1016/j.eururo.2012.09.002
Abern, Michael R., and Stephen J. Freedland. “Prostate cancer antigen 3 to select men for prostate biopsy: stop, go, or proceed with caution?” Eur Urol 63, no. 2 (February 2013): 210–11. https://doi.org/10.1016/j.eururo.2012.09.002.
Abern MR, Freedland SJ. Prostate cancer antigen 3 to select men for prostate biopsy: stop, go, or proceed with caution? Eur Urol. 2013 Feb;63(2):210–1.
Abern, Michael R., and Stephen J. Freedland. “Prostate cancer antigen 3 to select men for prostate biopsy: stop, go, or proceed with caution?” Eur Urol, vol. 63, no. 2, Feb. 2013, pp. 210–11. Pubmed, doi:10.1016/j.eururo.2012.09.002.
Abern MR, Freedland SJ. Prostate cancer antigen 3 to select men for prostate biopsy: stop, go, or proceed with caution? Eur Urol. 2013 Feb;63(2):210–211.
Published In
Eur Urol
DOI
EISSN
1873-7560
Publication Date
February 2013
Volume
63
Issue
2
Start / End Page
210 / 211
Location
Switzerland
Related Subject Headings
- Urology & Nephrology
- Prostatic Neoplasms
- Prostate
- Nomograms
- Male
- Humans
- Antigens, Neoplasm
- 3202 Clinical sciences
- 1103 Clinical Sciences